
Global R&D Pipeline
My Favorite
Hot Targets:
GnRHR
Back
Total number of drugs
113
Phase II and later clinical stages
29.2%
Involving companies
167
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Org-30850 | Org-30850 | Synthetic peptide | Other Diseases | Gonadotropin-releasing hormone receptor agonists | Merck Sharp & Dohme Corp. | Discontinued | Org-30850 | detail > | |||||||||||||
| Human luteinizing hormone releasing hormone-exotoxin of pseudomonas aeruginosa fusion protein | Human luteinizing hormone releasing hormone-exotoxin of pseudomonas aeruginosa fusion protein | Fusion protein | Neoplasms | Gonadotropin-releasing hormone receptor antagonists | Shenzhen Gaoke Biotechnology Co., Ltd. | IND Application | IND Application | Human luteinizing hormone releasing hormone-exotoxin of pseudomonas aeruginosa fusion protein | detail > | ||||||||||||
| Iturelix | Iturelix | Synthetic peptide | Neoplasms Urogenital Diseases | Gonadotropin-releasing hormone receptor antagonists | Merck Serono SA | Discontinued | Iturelix | detail > | |||||||||||||
| LHRH-PE40 | LHRH-PE40 | Fusion protein | Neoplasms | Elongation factor 2 inhibitors Gonadotropin-releasing hormone receptor antagonists | Jilin Yatai (Group) Co., Ltd. | Discontinued | Discontinued | LHRH-PE40 | detail > | ||||||||||||
| Nal-Glu | Nal-Glu | Chemical drugs | Gonadotropin-releasing hormone receptor antagonists | The Salk Institute for Biological Studies | Discontinued | Nal-Glu | detail > | ||||||||||||||
| NBI-42902 | NBI-42902 | Small molecule drug | Neoplasms Skin and Musculoskeletal Diseases Urogenital Diseases | Gonadotropin-releasing hormone receptor antagonists | Neurocrine Biosciences, Inc. | Discontinued | NBI-42902 | detail > | |||||||||||||
| NBI-70631 | NBI-70631 | Small molecule drug | Urogenital Diseases | Gonadotropin-releasing hormone receptor antagonists | Neurocrine Biosciences, Inc. | Discontinued | NBI-70631 | detail > | |||||||||||||
| Opigolix | Opigolix | Small molecule drug | Immune System Diseases Nervous System Diseases Skin and Musculoskeletal Diseases Urogenital Diseases Other Diseases | Gonadotropin-releasing hormone receptor antagonists | Astellas Pharma, Inc. | Phase 2 | Opigolix | detail > | |||||||||||||
| T-66 | T-66 | Small molecule drug | Neoplasms Urogenital Diseases | Gonadotropin-releasing hormone receptor agonists | Matrix Therapeutics | Discontinued | T-66 | detail > | |||||||||||||
| Sufugolix | Sufugolix | Small molecule drug | Neoplasms Urogenital Diseases | Gonadotropin-releasing hormone receptor antagonists | Takeda Pharmaceutical Co., Ltd. | Discontinued | Sufugolix | detail > |
Total 113 data
1
2
3
4
5
6
...
11
12


